Sandbox 124: Difference between revisions
No edit summary |
No edit summary |
||
| Line 57: | Line 57: | ||
ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to | ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to | ||
inhibit PBP2a because additional chemical groups at the | inhibit PBP2a because additional chemical groups at the | ||
<scene name='37/372724/ | <scene name='37/372724/Ceftobiprole/7'>R2</scene> | ||
position of the cephalosporin backbone are able to interact with additional amino acid | position of the cephalosporin backbone are able to interact with additional amino acid | ||
residues in PBP2a; specifically <scene name='37/372724/ | residues in PBP2a; specifically <scene name='37/372724/Tyr446_and_met641_label/1'>Tyr446 and Met641</scene>. | ||
As a result of its <scene name='37/372724/R2_interaction/3'>tighter binding</scene> to PBP2a, ceftobiprole | As a result of its <scene name='37/372724/R2_interaction/3'>tighter binding</scene> to PBP2a, ceftobiprole | ||
is able to more efficiently react with the serine active site residue and therefore inhibit the activity of PBP2a. | is able to more efficiently react with the serine active site residue and therefore inhibit the activity of PBP2a. | ||